276 related articles for article (PubMed ID: 18778291)
1. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell.
Linn YC; Lau SK; Liu BH; Ng LH; Yong HX; Hui KM
Immunology; 2009 Mar; 126(3):423-35. PubMed ID: 18778291
[TBL] [Abstract][Full Text] [Related]
2. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
4. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
5. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
[TBL] [Abstract][Full Text] [Related]
7. The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.
Chieregato K; Zanon C; Castegnaro S; Bernardi M; Amati E; Sella S; Rodeghiero F; Astori G
Blood Transfus; 2017 Jan; 15(1):93-100. PubMed ID: 27136441
[TBL] [Abstract][Full Text] [Related]
8. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
9. Selective reduction of natural killer cells and T cells expressing inhibitory receptors for MHC class I in the livers of patients with hepatic malignancy.
Norris S; Doherty DG; Curry M; McEntee G; Traynor O; Hegarty JE; O'Farrelly C
Cancer Immunol Immunother; 2003 Jan; 52(1):53-8. PubMed ID: 12536240
[TBL] [Abstract][Full Text] [Related]
10. A novel mechanism of antitumor response involving the expansion of CD3+/CD56+ large granular lymphocytes triggered by a tumor-expressed activating ligand.
Costello RT; Sivori S; Mallet F; Sainty D; Arnoulet C; Reviron D; Gastaut JA; Moretta A; Olive D
Leukemia; 2002 May; 16(5):855-60. PubMed ID: 11986947
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
Poh SL; Linn YC
Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
[TBL] [Abstract][Full Text] [Related]
12. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation.
Alvarnas JC; Linn YC; Hope EG; Negrin RS
Biol Blood Marrow Transplant; 2001; 7(4):216-22. PubMed ID: 11349808
[TBL] [Abstract][Full Text] [Related]
13. Significance of Frequencies, Compositions, and/or Antileukemic Activity of (DC-stimulated) Invariant NKT, NK and CIK Cells on the Outcome of Patients With AML, ALL and CLL.
Boeck CL; Amberger DC; Doraneh-Gard F; Sutanto W; Guenther T; Schmohl J; Schuster F; Salih H; Babor F; Borkhardt A; Schmetzer H
J Immunother; 2017; 40(6):224-248. PubMed ID: 28557814
[TBL] [Abstract][Full Text] [Related]
14. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts.
Linn YC; Lau LC; Hui KM
Br J Haematol; 2002 Jan; 116(1):78-86. PubMed ID: 11841399
[TBL] [Abstract][Full Text] [Related]
15. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells.
Mehta BA; Schmidt-Wolf IG; Weissman IL; Negrin RS
Blood; 1995 Nov; 86(9):3493-9. PubMed ID: 7579455
[TBL] [Abstract][Full Text] [Related]
16. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
17. Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression.
Ortaldo JR; Winkler-Pickett RT; Yagita H; Young HA
Cell Immunol; 1991 Sep; 136(2):486-95. PubMed ID: 1714795
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
19. Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells.
Hongeng S; Petvises S; Worapongpaiboon S; Rerkamnuaychoke B; Pakakasama S; Jootar S
Int J Hematol; 2003 Feb; 77(2):175-9. PubMed ID: 12627854
[TBL] [Abstract][Full Text] [Related]
20. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]